MorphoSys AG (MOR)
- Previous Close
17.87 - Open
17.96 - Bid 17.99 x 100
- Ask 18.04 x 100
- Day's Range
17.92 - 18.03 - 52 Week Range
4.18 - 18.31 - Volume
187,789 - Avg. Volume
530,827 - Market Cap (intraday)
2.724B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-1.49 - Earnings Date Aug 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.52
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
www.morphosys.comRecent News: MOR
Performance Overview: MOR
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MOR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MOR
Valuation Measures
Market Cap
2.72B
Enterprise Value
2.67B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.65
Price/Book (mrq)
51.52
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-190.61%
Return on Assets (ttm)
-13.84%
Return on Equity (ttm)
--
Revenue (ttm)
241.47M
Net Income Avi to Common (ttm)
-468.57M
Diluted EPS (ttm)
-1.49
Balance Sheet and Cash Flow
Total Cash (mrq)
630.77M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
98.9M
Research Analysis: MOR
Company Insights: MOR
MOR does not have Company Insights